RegeneRx Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye Syndrome
- Monday, April 9, 2018, 6:05
- Finance
- Add a comment
ROCKVILLE, Md., April 9, 2018 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the outcome of discussions between its U.S. joint…
Source: https://www.prnewswire.com/news-releases/regenerx-announces-outcome-of-fda-discussions-for-development-of-rgn-259-for-dry-eye-syndrome-300626077.html
About the Author
adminasapcorp has written 39063 stories on this site.